Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- 41 Financing Alzheimer’s Disease Drug Development
- 42 Valley of Death and the Role of Venture Philanthropy in Alzheimer’s Disease Drug Development
- 43 Alzheimer’s Association Funding and Policy for Alzheimer’s Disease Drug Development
- 44 The Role of Philanthropy in Alzheimer’s Disease Therapeutic Development
- 45 National Institute on Aging’s Alzheimer’s Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer’s Disease and Related Dementias
- 46 Alzheimer ’s Disease Drug Discovery and the Evolution of Start-Up Biotechnology Companies: Cognition Therapeutics, Inc. as a Case Study
- 47 Introduction to Venture Capital in Alzheimer’s Disease Drug Development
- 48 Federal Small Business Support for Small Businesses Pursuing Alzheimer’s Disease Drug Development
- Index
- References
48 - Federal Small Business Support for Small Businesses Pursuing Alzheimer’s Disease Drug Development
from Section 7 - Funding and Financing Alzheimer’s Disease Drug Development
Published online by Cambridge University Press: 03 March 2022
Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- 41 Financing Alzheimer’s Disease Drug Development
- 42 Valley of Death and the Role of Venture Philanthropy in Alzheimer’s Disease Drug Development
- 43 Alzheimer’s Association Funding and Policy for Alzheimer’s Disease Drug Development
- 44 The Role of Philanthropy in Alzheimer’s Disease Therapeutic Development
- 45 National Institute on Aging’s Alzheimer’s Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer’s Disease and Related Dementias
- 46 Alzheimer ’s Disease Drug Discovery and the Evolution of Start-Up Biotechnology Companies: Cognition Therapeutics, Inc. as a Case Study
- 47 Introduction to Venture Capital in Alzheimer’s Disease Drug Development
- 48 Federal Small Business Support for Small Businesses Pursuing Alzheimer’s Disease Drug Development
- Index
- References
Summary
Early-stage drug development efforts for Alzheimer’s disease (AD) therapeutics often occur within academia and start-up companies and are often supported by National Institutes of Health (NIH) funding. The National Institute on Aging’s (NIA’s) seed funding through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs provide innovators with non-dilutive funding that supports key early-stage drug developments. Since 2015, the NIA small business funding programs have become a valuable source of seed funding available that enabled start-up companies to reach critical value inflection points. This chapter includes examples of five companies that received NIA small business funding at the preclinical stage of development and advanced their innovations to clinical trials: AgeneBio, Alector, Avid Radiopharmaceuticals, Cognition Therapeutics and Tetra Therapeutics. The NIH and NIA have launched several strategic initiatives and funding opportunities to enable small businesses to reach key value inflection points.
Keywords
- Type
- Chapter
- Information
- Alzheimer's Disease Drug DevelopmentResearch and Development Ecosystem, pp. 533 - 543Publisher: Cambridge University PressPrint publication year: 2022
References
Deb, A, Thornton, JD, Sambamoorthi, U, Innes, K. Direct and indirect cost of managing Alzheimer’s disease and related dementias in the United States. Expert Rev Pharmacoecon Outcomes Res 2017; 17: 189–202.CrossRefGoogle ScholarPubMed
Hurd, MD, Martorell, P, Delavande, A, Mullen, KJ, Langa, KM. Monetary costs of dementia in the United States. N Engl J Med 2013; 368: 1326–34.Google Scholar
US Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation. National plans to address Alzheimer’s disease. 2012. Available at: https://aspe.hhs.gov/napa-national-plans (accessed December 7, 2021).Google Scholar
Ghazarian, A, Haim, T, Sauma, S, Katiyar, P. National Institute on Aging seed funding enables Alzheimer’s disease startups to reach key value inflection points. Alzheimers Dement 2021;DOI: https://doi.org/10.1002/alz.12392.Google Scholar
Mauricio, R, Benn, C, Davis, J, et al. Therapeutics for dementia: tackling gaps in developing life-changing treatments for dementia. Alzheimers Dement (N Y) 2019; 5: 241–53.Google ScholarPubMed
Scott, TJ, O’Connor, AC, Link, AN, Beaulieu, TJ. Economic analysis of opportunities to accelerate Alzheimer’s disease research and development. Ann N Y Acad Sci 2014; 1313: 17–34.Google Scholar
Cummings, J, Reiber, C, Kumar, P. The price of progress: funding and financing Alzheimer’s disease drug development. Alzheimers Dement (N Y) 2018; 4: 330–43.Google Scholar
US Small Business Administration. Birth and history of the SBIR program. Available at: www.sbir.gov/birth-and-history-of-the-sbir-program (accessed November 10, 2021).Google Scholar
Onken, J, Miklos, AC, Dorsey, TF, et al. Using database linkages to measure innovation, commercialization, and survival of small businesses. Eval Program Plann 2019; 77: 101710.Google Scholar
US Small Business Administration. About SBA. Available at: www.sba.gov/about-sba (accessed November 3, 2020).Google Scholar
US Small Business Administration. Performance benchmark requirements for Phase I. Available at: www.sbir.gov/performance-benchmarks (accessed November 10, 2020).Google Scholar
National Science Board. Science and Engineering Indicators. 2018: research and development – US trends and international comparisons. Available at: www.nsf.gov/statistics/2018/nsb20181/ (accessed November 10, 2020).Google Scholar
Jefferson, RS. How the largest public funder of biomedical research in the world spends your money. Available at: www.forbes.com/sites/robinseatonjefferson/2018/12/21/how-the-largest-public-funder-of-biomedical-research-in-the-world-spends-your-money/?sh=69d3d48f27b9 (accessed November 23, 2020).Google Scholar
NIH Research Portfolio Online Reporting Tools (RePORT). Small business research (SBIR/STTR). Available at: https://report.nih.gov/nihdatabook/category/8 (accessed November 23, 2020).Google Scholar
National Institutes of Health. Intellectual property and iEdison invention report requirements. Available at: https://sbir.nih.gov/policy/invention-reporting (accessed December 2, 2020).Google Scholar
Ben-Menachem, G, Ferguson, SM, Balakrishnan, K. Doing business with the NIH. Nat Biotechnol 2006; 24: 17–20.Google Scholar
National Institutes of Health. Advancing research on Alzheimer’s disease (AD) and Alzheimer’s-disease-related dementias (ADRD) (R41/R42). Available at: https://grants.nih.gov/grants/guide/pa-files/PAs-17-065.html (accessed November 10, 2020).Google Scholar
National Institutes of Health. Advancing research on Alzheimer’s disease (AD) and Alzheimer’s-disease-related dementias (ADRD) (R43/R44). Available at: https://grants.nih.gov/grants/guide/pa-files/PAs-17-064.html (accessed November 10, 2020).Google Scholar
Cole, MA, Seabrook, GR. On the horizon: the value and promise of the global pipeline of Alzheimer’s disease therapeutics. Alzheimers Dement (N Y) 2020; 6: e12009.Google Scholar
Bakker, A, Krauss, GL, Albert, MA, et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 2012; 74: 467–74.Google Scholar
Cognition Therapeutics. Cognition Therapeutics receives $75.8 million NIA grant for 540-patient Phase 2 study of CT1812 in collaboration with the Alzheimer’s Clinical Trials Consortium. Available at: https://cogrx.com/cognition-receives-nia-grant-for-actc-study/ (accessed December 2, 2020).Google Scholar
Businesswire. Tetra Therapeutics and Shionogi announce expanded alliance. Available at: www.businesswire.com/news/home/20200306005082/en/Tetra-Therapeutics-Shionogi-Announce-Expanded-Alliance (accessed December 2, 2021).Google Scholar
Canaria, CA, Portilla, L, Weingarten, M. I-Corps at NIH: entrepreneurial training program creating successful small businesses. Clin Transl Sci 2019; 12: 324–8.CrossRefGoogle ScholarPubMed
Cummings, J, Lee, G, Ritter, A, Sabbagh, M, Zhong, K. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement (N Y) 2019; 5: 272–93.Google Scholar